Frontlight ResearchEarly access
CompletedPhase 2
Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps
Key facts
- Who runs it
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 114 people enrolled
- Started
- 4 Sept 2023
- Ended
- 21 Jan 2026
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- SHR-1905 Injection
- SHR-1905 Placebo Injection
- Record updated
- 22 July 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Weight ≥40kg
- Diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP)
- Bilateral nasal polyps at screening and baseline, total NPS ≥5, ≥2 points for each nostril
- NCS ≥2 at screening and baseline
- SNOT-22≥20 at screening period and baseline
- Recorded persistent NP symptoms for over 4 weeks prior to screening
- Subjects received standard therapy with intranasal corticosteroids (INCS) and remained stable during the 4 weeks prior to randomization
- NP surgery in the past and/or ACERS treated with SCS occurred within 2 years before randomization (or with contraindications/ intolerances)
Who cannot take part
- Concomitant with immunodeficiency
- Concomitant with contraindications or not suitable for nasal endoscopy
- Infection within 2 weeks prior to screening to randomization that is clinically significant and/or should be treated with systemic antibiotics
- Uncontrolled epistaxis within 4 weeks prior to randomization
- Major surgery performed within 3 months prior to randomization, or surgery planned during the study, or treatments that may affect evaluations according to investigators
- Parasitic infection within 6 months before randomization
- Sinus or intranasal surgery (except for diagnostic biopsy) within 6 months prior to randomization, or changes in the nasal walls caused by sinus or intranasal surgery that made NPS evaluation impossible
- Concomitant with active hepatitis B, positive hepatitis C virus antibodies, positive human immunodeficiency virus antibodies, or positive treponema pallidum antibodies
- Transfusion of blood products or immunoglobulin within 4 weeks prior to randomization
- SCS or additional INCS use within 4 weeks before randomization, or planned use during treatment period
- Regular use of decongestants (local or systemic) within 4 weeks before randomization, except for during the endoscopic procedure
- Adnimistration of live vaccine or viral vector vaccine within 4 weeks before randomization
- Allergen immunotherapy within 8 weeks before randomization
- Substance abuse, drug abuse, and/or excessive alcohol consumption within 1 year prior to randomization
- Uncontrolled hypertension
- Uncontrolled diabetes
- Malignancies diagnosed within 5 years before randomization (except those with a low risk of metastasis or death)
- Abnormalities of laboratory tests at screening or baseline
- Prolonged QTc interval (>450ms for male and >470ms for female) or other clinically significant abnormal results of ECG at screening or baseline that may cause significant safety risks to subjects
- Any comorbidities that may affect the efficacy evaluation of nasal polyps
- Any comorbidities except for asthma that may affect blood EOS levels
- FEV1 before the use of bronchodilator (pre-BD) was less than 50% at screening
- Smoking history ≥10 pack-years, smoking at screening, or smoking cessation less than 6 months at screening
- Pregnancy (including positive pregnancy test at screening or baseline), lactation, or pregnancy plan during study period
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to explore the reasonable dosage of SHR-1905 injection for CRSwNP.
The 4 groups in the trial
- Treatment group A: SHR-1905 Injection(dose 1)Treatment being tested
Treatment: SHR-1905 Injection
- Treatment group B: SHR-1905 Injection(dose 2)Treatment being tested
Treatment: SHR-1905 Injection
- Treatment group C: SHR-1905 Injection(dose 3)Treatment being tested
Treatment: SHR-1905 Injection
- Placebo GroupPlacebo, for comparison
Treatment: SHR-1905 Placebo Injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Efficacy and Safety Study of SHR-1905 in Patiens With Chronic Rhinosinusitis With Nasal Polyps
- Record updated
- 22 July 2026